Abstract
The pathophysiology of Asian diabetic patients differs from that in Western patients. However, the majority of studies for treatment in type 2 diabetes have been performed predominantly in Western populations, and the researches in Chinese or Asian patients are limited. We discuss the mechanisms of different glucagon-like peptide 1 receptor agonist(GLP-1RA), and describe the available clinical data for the treatment of basal insulin in combination with the short-acting GLP-1RA lixisenatide, especially for Asian patients with type 2 diabetes mellitus.The current paper is a Chinese translation of a review entitled as What next after basal insulin? Treatment intensification with lixisenatide in Asian patients with type 2 diabetes mellitus published in 《Journal of Diabetes》 (2017, 9: 562-574) with the permission from the the journal. (Chin J Endocrinol Metab, 2017, 33: 790-797) Key words: Insulin; Lixisenatide; Diabetes mellitus, type 2
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
